Sumitomo Pharma Shares Plunge Despite Parkinson's Treatment Greenlight

Shares of Japan's Sumitomo Pharma fell over 12% due to profit-taking, even after a specialist panel endorsed its iPS cell-based therapy for Parkinson's.

20 Feb, 02:26 — 20 Feb, 02:26